尽管性别肯定护理有所增加，但我们对跨性别女性 (TGW) 前列腺癌 (PCa) 的了解仍处于起步阶段。健康差异以及缺乏前列腺癌意识和筛查可能是为这一人群提供优质护理的障碍。此外，激素控制对 TGW 中 PCa 侵袭性的影响尚待确定。本研究旨在通过两个国家数据集比较跨性别和顺性别 (CG) 前列腺癌患者的肿瘤学特征和生存结果。退伍军人事务信息学和计算基础设施数据库（1999-2020 年）以及监测、流行病学和最终结果-审查了医疗保险数据库（2010-2017）。分析了人口统计学和临床​​细节。对倾向评分匹配组进行逻辑回归分析，以确定 PCa 患者高风险疾病和转移的预测因子。根据年龄、种族、诊断年份和查尔森合并症指数评分，各组按 5:1 (CG:TGW) 进行匹配。主要结局包括转移表现、高风险局部疾病、总生存期 (OS) 和前列腺癌特异性死亡率 (PCSM)。总共纳入 1194 名患者（199 名 TGW；995 CG）。跨性别身份与转移表现（比值比 [OR]，0.38；p = .2）、高风险局部疾病（OR，1.19；p = .50）或 PCSM（风险比 [HR]，0.65；p = .50）之间的关联= .3) 未检测到。跨性别身份与 OS 改善相关（HR，0.67；p = .014）。TGW 和 CG 男性之间的 PCa 特异性结果似乎具有可比性，尽管该研究不足以检测到适度的差异。有必要进一步调查 TGW 中 PCa 的发病率和结果。© 2024 美国癌症协会。

Despite the rise in gender-affirming care, our understanding of prostate cancer (PCa) in transgender women (TGW) remains in its infancy. Health disparities and lack of PCa awareness and screening are possible barriers to providing quality care for this population. In addition, the implication of hormonal manipulation for the aggressiveness of PCa in TGW is yet to be determined. Here, this study sought to compare oncological characteristics and survival outcomes between transgender and cisgender (CG) patients with PCa via two national data sets.The Veterans Affairs Informatics and Computing Infrastructure database (1999-2020) and the Surveillance, Epidemiology, and End Results-Medicare database (2010-2017) were reviewed. Demographic and clinical details were analyzed. Logistic regression analysis was performed on propensity score-matched groups to identify predictors of high-risk disease and metastasis in patients with PCa. Groups were matched 5:1 (CG:TGW) on the basis of age, race, year of diagnosis, and Charlson Comorbidity Index score. Primary outcomes included metastatic presentation, high-risk localized disease, overall survival (OS), and prostate cancer-specific mortality (PCSM).A total of 1194 patients were included (199 TGW; 995 CG). Associations between transgender identity and metastatic presentation (odds ratio [OR], 0.38; p = .2), high-risk localized disease (OR, 1.19; p = .50), or PCSM (hazard ratio [HR], 0.65; p = .3) were not detected. Transgender identity was associated with improved OS (HR, 0.67; p = .014).PCa-specific outcomes seem comparable between TGW and CG men, although the study was underpowered to detect modest differences. Further investigation into the incidence and outcomes of PCa in TGW is warranted.© 2024 American Cancer Society.